局部血管肉瘤,不是一种疾病:根据原发部位和病因判断预后的单中心回顾性研究

Q2 Medicine Sarcoma Pub Date : 2021-09-10 eCollection Date: 2021-01-01 DOI:10.1155/2021/9960085
Inna Schott, Sven-Thorsten Liffers, Farhad Farzaliyev, Johanna Falkenhorst, Hans-Ulrich Steinau, Jürgen-Walter Treckmann, Lars Erik Podleska, Christoph Pöttgen, Hans-Ulrich Schildhaus, Marit Ahrens, Uta Dirksen, Fatma-Zehra Murat, Jens T Siveke, Sebastian Bauer, Rainer Hamacher
{"title":"局部血管肉瘤,不是一种疾病:根据原发部位和病因判断预后的单中心回顾性研究","authors":"Inna Schott, Sven-Thorsten Liffers, Farhad Farzaliyev, Johanna Falkenhorst, Hans-Ulrich Steinau, Jürgen-Walter Treckmann, Lars Erik Podleska, Christoph Pöttgen, Hans-Ulrich Schildhaus, Marit Ahrens, Uta Dirksen, Fatma-Zehra Murat, Jens T Siveke, Sebastian Bauer, Rainer Hamacher","doi":"10.1155/2021/9960085","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Angiosarcomas are rare and heterogeneous tumors with poor prognosis. The clinical subtypes are classified depending on the primary site and etiology.</p><p><strong>Methods: </strong>We conducted a retrospective, monocentric study of 136 patients with localized AS between May 1985 and November 2018. Overall survival (OS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS) were estimated using the Kaplan-Meier method. To identify prognostic factors, univariate and multivariate analyses were performed based on Cox regressions.</p><p><strong>Results: </strong>The median age was 67 years (19-72.8 years). Primary sites were cutaneous (27.2%), breast (38.2%), and deep soft tissue (34.6%). The majority was primary angiosarcomas (55.9%) followed by postradiation (40.4%) and chronic lymphedema angiosarcomas (2.9%). Prognosis significantly differed depending on the primary site and etiology. Shortest median OS and MFS were observed in deep soft tissue angiosarcomas, whereas cutaneous angiosarcomas, angiosarcomas of the breast, and radiation-associated angiosarcomas displayed worse median LRFS. Univariate analyses showed better OS for tumor size <10 cm (<i>p</i> = 0.009), negative surgical margins (<i>p</i> = 0.021), and negative lymph node status (<i>p</i> = 0.007). LRFS and MFS were longer for tumor size <10 cm (<i>p</i> = 0.012 and <i>p</i> = 0.013). In multivariate analyses, age <70 years was the only independent positive prognostic factor for OS in all subgroups. For LRFS, secondary AS of the breast was a negative prognostic factor (HR: 2.35; <i>p</i> = 0.035).</p><p><strong>Conclusions: </strong>Different behaviors and prognoses depending on the primary site and etiology should be considered for the treatment of this heterogeneous disease. In cutaneous angiosarcomas of the head/neck and postradiation angiosarcomas of the breast, local recurrence seems to have a crucial impact on OS. Therefore, improved local therapies and local tumor staging may have to be implemented. However, in deep soft tissue angiosarcomas, distant recurrence seems to have a major influence on prognosis, which indicates a benefit of additional perioperative chemotherapy.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"9960085"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449723/pdf/","citationCount":"0","resultStr":"{\"title\":\"Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology.\",\"authors\":\"Inna Schott, Sven-Thorsten Liffers, Farhad Farzaliyev, Johanna Falkenhorst, Hans-Ulrich Steinau, Jürgen-Walter Treckmann, Lars Erik Podleska, Christoph Pöttgen, Hans-Ulrich Schildhaus, Marit Ahrens, Uta Dirksen, Fatma-Zehra Murat, Jens T Siveke, Sebastian Bauer, Rainer Hamacher\",\"doi\":\"10.1155/2021/9960085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Angiosarcomas are rare and heterogeneous tumors with poor prognosis. The clinical subtypes are classified depending on the primary site and etiology.</p><p><strong>Methods: </strong>We conducted a retrospective, monocentric study of 136 patients with localized AS between May 1985 and November 2018. Overall survival (OS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS) were estimated using the Kaplan-Meier method. To identify prognostic factors, univariate and multivariate analyses were performed based on Cox regressions.</p><p><strong>Results: </strong>The median age was 67 years (19-72.8 years). Primary sites were cutaneous (27.2%), breast (38.2%), and deep soft tissue (34.6%). The majority was primary angiosarcomas (55.9%) followed by postradiation (40.4%) and chronic lymphedema angiosarcomas (2.9%). Prognosis significantly differed depending on the primary site and etiology. Shortest median OS and MFS were observed in deep soft tissue angiosarcomas, whereas cutaneous angiosarcomas, angiosarcomas of the breast, and radiation-associated angiosarcomas displayed worse median LRFS. Univariate analyses showed better OS for tumor size <10 cm (<i>p</i> = 0.009), negative surgical margins (<i>p</i> = 0.021), and negative lymph node status (<i>p</i> = 0.007). LRFS and MFS were longer for tumor size <10 cm (<i>p</i> = 0.012 and <i>p</i> = 0.013). In multivariate analyses, age <70 years was the only independent positive prognostic factor for OS in all subgroups. For LRFS, secondary AS of the breast was a negative prognostic factor (HR: 2.35; <i>p</i> = 0.035).</p><p><strong>Conclusions: </strong>Different behaviors and prognoses depending on the primary site and etiology should be considered for the treatment of this heterogeneous disease. In cutaneous angiosarcomas of the head/neck and postradiation angiosarcomas of the breast, local recurrence seems to have a crucial impact on OS. Therefore, improved local therapies and local tumor staging may have to be implemented. However, in deep soft tissue angiosarcomas, distant recurrence seems to have a major influence on prognosis, which indicates a benefit of additional perioperative chemotherapy.</p>\",\"PeriodicalId\":21431,\"journal\":{\"name\":\"Sarcoma\",\"volume\":\"2021 \",\"pages\":\"9960085\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449723/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sarcoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/9960085\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/9960085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:血管肉瘤是一种罕见的异质性肿瘤,预后较差。临床亚型根据原发部位和病因进行分类:我们对1985年5月至2018年11月期间的136例局部AS患者进行了回顾性、单中心研究。采用 Kaplan-Meier 法估算了总生存期(OS)、无局部复发生存期(LRFS)和无转移生存期(MFS)。为了确定预后因素,根据 Cox 回归进行了单变量和多变量分析:中位年龄为 67 岁(19-72.8 岁)。原发部位为皮肤(27.2%)、乳腺(38.2%)和深部软组织(34.6%)。大多数是原发性血管肉瘤(55.9%),其次是放疗后血管肉瘤(40.4%)和慢性淋巴水肿血管肉瘤(2.9%)。根据原发部位和病因的不同,预后也明显不同。深部软组织血管肉瘤的中位OS和MFS最短,而皮肤血管肉瘤、乳腺血管肉瘤和放射相关血管肉瘤的中位LRFS较差。单变量分析显示,肿瘤大小(P = 0.009)、手术切缘阴性(P = 0.021)和淋巴结状态阴性(P = 0.007)的患者OS较好。肿瘤大小(p = 0.012 和 p = 0.013)的 LRFS 和 MFS 更长。在多变量分析中,年龄 p = 0.035):结论:在治疗这种异质性疾病时,应根据原发部位和病因考虑不同的行为和预后。在头颈部皮肤血管肉瘤和乳腺放疗后血管肉瘤中,局部复发似乎对OS有着至关重要的影响。因此,必须改进局部疗法和局部肿瘤分期。然而,在深部软组织血管肉瘤中,远处复发似乎对预后有重大影响,这表明围手术期额外化疗的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology.

Background: Angiosarcomas are rare and heterogeneous tumors with poor prognosis. The clinical subtypes are classified depending on the primary site and etiology.

Methods: We conducted a retrospective, monocentric study of 136 patients with localized AS between May 1985 and November 2018. Overall survival (OS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS) were estimated using the Kaplan-Meier method. To identify prognostic factors, univariate and multivariate analyses were performed based on Cox regressions.

Results: The median age was 67 years (19-72.8 years). Primary sites were cutaneous (27.2%), breast (38.2%), and deep soft tissue (34.6%). The majority was primary angiosarcomas (55.9%) followed by postradiation (40.4%) and chronic lymphedema angiosarcomas (2.9%). Prognosis significantly differed depending on the primary site and etiology. Shortest median OS and MFS were observed in deep soft tissue angiosarcomas, whereas cutaneous angiosarcomas, angiosarcomas of the breast, and radiation-associated angiosarcomas displayed worse median LRFS. Univariate analyses showed better OS for tumor size <10 cm (p = 0.009), negative surgical margins (p = 0.021), and negative lymph node status (p = 0.007). LRFS and MFS were longer for tumor size <10 cm (p = 0.012 and p = 0.013). In multivariate analyses, age <70 years was the only independent positive prognostic factor for OS in all subgroups. For LRFS, secondary AS of the breast was a negative prognostic factor (HR: 2.35; p = 0.035).

Conclusions: Different behaviors and prognoses depending on the primary site and etiology should be considered for the treatment of this heterogeneous disease. In cutaneous angiosarcomas of the head/neck and postradiation angiosarcomas of the breast, local recurrence seems to have a crucial impact on OS. Therefore, improved local therapies and local tumor staging may have to be implemented. However, in deep soft tissue angiosarcomas, distant recurrence seems to have a major influence on prognosis, which indicates a benefit of additional perioperative chemotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sarcoma
Sarcoma Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
5.00
自引率
0.00%
发文量
15
审稿时长
14 weeks
期刊介绍: Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.
期刊最新文献
Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients. Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States. Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients. ATRX and Its Prognostic Significance in Soft Tissue Sarcoma. Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1